

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Yap, Jeffrey T.		POSITION TITLE	
eRA COMMONS USER NAME (credential, e.g., agency login) jeff yap		Assistant Professor of Radiology	
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
University of Dallas	B.S.	1988	Physics
University of Chicago	Ph.D.	1998	Medical Physics

A. Positions and Honors.**Positions and Employment**

1996-1999	Scientific Research Associate (RAIA), Head of methodology, PET Oncology Group, MRC Cyclotron Unit, Hammersmith Hospital, London, UK.
1999-2000	Scientific Research Fellow (Promoted to RAI), Head of methodology, PET Oncology Group, MRC Cyclotron Unit, Hammersmith Hospital.
2001-2003	Assistant Professor, Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
2001-2003	Physicist, PET Facility, Department of Radiology, UPMC Health System, Pittsburgh, PA.
2003-2005	Associate Professor, Departments of Medicine and Radiology, University of Tennessee Medical Center, Knoxville, TN.
2003-2005	Adjunct Associate Professor, Department of Physics, University of Tennessee, Knoxville, TN.
6/2005-	Assistant Professor, Harvard Medical School, Boston, MA
6/2005-	Senior Diagnostic Physicist, Department of Radiology, Dana-Farber Cancer Institute, Boston, MA

Other Experience and Professional Activities

Member: American Association of Physicists in Medicine, Society of Nuclear Medicine

Guest Associate Editor: Medical Physics, 2005-2008.

Speaker/Panelist: NIH/NCI National Forum on Biomedical Imaging in Oncology, 1/31/2002.

Speaker/Panelist: NIH/NCI The Role of Biological Imaging for Radiation Oncology Workshop, 4/25-27/2002.

Reviewer: NIH/NCI Program Project Grant (P01), 10/21/2002-10/23/2002.

Reviewer: NIH/NCI Program Project Grant (P01), 5/14/2003.

Ad-Hoc Member: NIH/NCI Subcommittee E, 7/29/2003-7/30/2003.

Speaker/Panelist NIH/NCI Workshop on The Role of FDG-PET in the Evaluation of Therapeutic Response in Cancer, 9/10/2004.

Reviewer: NIH/NCI Program Project Grant (P01), 9/26/05-9/27/05.

B. Selected peer-reviewed publications (in chronological order).

1. L.K. Shankar, A. Van den Abbeele, J. Yap, R. Benjamin, S. Scheutze, T.J. FitzGerald. Considerations for the Use of ImagingTools for Phase II Treatment Trials in Oncology. Clin Cancer Res 15(6): 1891-1897, 2009.
2. N. Raje, S.B. Woo, K. Hande, J.T. Yap, P.G. Richardson, S. Vallet, N. Treister, T. Hideshima, N. Sheehy, S. Chhetri, B. Connell, W. Xie, Y.T. Tai, A. Szot-Barnes, M. Tian, R.L. Schlossman, E. Weller, N.C. Munshi, AD Van Den Abbeele, KC Anderson. Clinical, radiographic, and biochemical

- characterization of multiple myeloma patients with osteonecrosis of the jaw. *Clin Cancer Res*, 14(8):2387-95, 2008.
3. S. Masciari, A.D. Van den Abbeele, L.R. Diller, I. Rastarhuyeva, J. Yap, K. Schneider, L. Digianni, F.P. Li, J.F. Fraumeni Jr, S. Syngal, J.E. Garber. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. *JAMA*, 299(11):1315-9, 2008.
 4. L.K. Shankar, J.M. Hoffman, S. Bacharach, M.M. Graham, J. Karp, A.A. Lammertsma, S. Larson, D.A. Mankoff, B.A. Siegel, A. Van den Abbeele, J. Yap, D. Sullivan. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. *J. Nucl Med*, 47(6): 1059-1066, 2006.
 5. J.S. Wall, S.J. Kennel, M. Paulus, J. Gregor, T. Richey, J. Avenell, J. Yap, D. Townsend, D.T. Weiss and A. Solomon. Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. *J Nucl Med*, 47(12):2016-2024, 2006.
 6. J.T. Yap, J.P.J. Carney, N.C. Hall, D.W. Townsend. Image-guided cancer therapy using PET/CT. *Cancer J*, 10:221-233, 2004.
 7. D.W. Townsend, J.P.J. Carney, J.T. Yap, N.C. Hall. PET/CT today and tomorrow. *J Nucl Med*, 45(1):4S-14S, 2004.
 8. C.-M. Kao, J.T. Yap, J. Mukherjee, M.N. Wernick. Image reconstruction for dynamic PET based on low-order approximation and restoration of the sinogram. *IEEE Trans. Med. Imag.*, 16:738-749, 1997.
 9. H. Anderson, J.T. Yap, P. Wells, M.P. Miller, D. Propper, P. Price, A.L. Harris. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. *Brit J Cancer*, 89:262-267, 2003.
 10. P.A. Kaufmann, T. Gneccchi-Ruscione, J.T. Yap, P.G. Camici. Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with oxygen-15 labeled water and PET. *J Nucl Med*, 40(11):1848-1856, 1999.
 11. R.N. Gunn, J.T. Yap, P.W. Wells, S. Osman, P. Price, T. Jones, V.J. Cunningham. Tissue metabolite measurement correction in PET studies. *J Nucl Med*, 41(4):706-711, 2000.
 12. R.N. Gunn, A. Ranicar, J.T. Yap, P. Wells, S. Osman, T. Jones, V.J. Cunningham. On-line measurement of exhaled [11C]carbon dioxide during PET scans. *J Nucl Med*, 41(4):605-611, 2000.
 13. A. Saleem, J.T. Yap, S. Osman, G. Brown, F. Brady, S.K. Luthra, M. O'Callaghan, B. Suttle, S.V. Lucas, T. Jones, P.M. Price, E.O. Aboagye. In vivo imaging of drug action in patients: Modulation of 5-fluorouracil tissue pharmacokinetics by the dihydropyrimidine dehydrogenase inactivator eniluracil. *Lancet* 355:2125-2131, 2000.
 14. H. Anderson, J.T. Yap, V.J. Cunningham, T. Jones, P. Price. Assessment of pharmacodynamic vascular response using PET in a phase I trial of combretastatin A4 phosphate. *J Clin Onc*, 12(15):2823-30, 2003.

C. Research Support.

Completed Research Support

2003-2005 "A high performance PET and CT tomograph." National Cancer Institute R33 CA94317. Role: Co-Investigator (PI: David Townsend).

2004-2005 "Evaluation of the biodistribution and radiation dosimetry of a novel PET radiotracer for imaging primary (AL) amyloidosis." The Physicians' Medical Education and Research Foundation. Role: Co-Principal Investigator (Co-PI: Jonathan Wall).